18 and older, any sex, with Uveitis or Uveitis, Posterior. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Time to Additional Therapy for UveitisPrimary· 6 months following completion of the Parent study CLS1001-301 (NCT02595398), for a total of up to 1 year
This time to event outcome was calculated as the number of days between the date of initiation of additional therapy for uveitis and the date of first treatment in the Parent study CLS1001-301 (NCT02595398).
Group
Value
95% CI
4 mg CLS-TA Suprachoriodal Injection
344.0
282.0 – NA
Sham Procedure
332.0
280.0 – NA
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse EventsSecondary· 6 months following exit from Parent study
Number of participants with treatment emergent adverse events and serious adverse events reported during the extension study.
Treatment-emergent adverse events
Group
Value
95% CI
4 mg CLS-TA Suprachoriodal Injection
16
Sham Procedure
3
Serious adverse events
Group
Value
95% CI
4 mg CLS-TA Suprachoriodal Injection
1
Sham Procedure
0
Mean Change From Baseline in Central Subfield ThicknessSecondary· 6 months following exit from Parent study
Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.
Group
Value
95% CI
4 mg CLS-TA Suprachoriodal Injection
-174.5
± 145.70
Sham Procedure
19.5
± 0.71
Mean Change From Baseline in Best Corrected Visual AcuitySecondary· 6 months following exit from Parent study
Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.
Group
Value
95% CI
4 mg CLS-TA Suprachoriodal Injection
12.1
± 13.00
Sham Procedure
14.0
± 15.56
Adverse events — posted to ClinicalTrials.gov
Time frame: 6 months following completion of the Parent study CLS1001-301 (NCT02595398), for a total of up to 1 year..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspension, for the treatment of macular edema associated with non-infectious uveitis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of 4 mg CLS-TA Suprachoriodal Injection
Trials testing the same drug.
NCT03097315 — Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
· Phase 3
· completed
Other recruiting trials for Uveitis
Currently open trials in the same condition.
NCT07262437 — Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
· NA
· active not recruiting
NCT07176130 — Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore
· active not recruiting
NCT06974162 — Metagenomics for Ocular Inflammation
· recruiting
NCT06431373 — A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
· Phase 3
· active not recruiting
NCT06310837 — Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
· NA
· active not recruiting
Other Clearside Biomedical, Inc. trials
Trials by the same sponsor.
NCT05891548 — Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
· Phase 2
· completed
NCT05131646 — Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
· completed
NCT04626128 — Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
· Phase 1, PHASE2
· completed
NCT03203447 — Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
· Phase 3
· terminated
NCT03126786 — Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clearside Biomedical, Inc.
Last refreshed: 2 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02952001.